Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4567-70. doi: 10.1016/j.bmcl.2012.05.106. Epub 2012 Jun 6.
Probestin is a potent aminopeptidase N (APN) inhibitor. Four probestin conjugates containing a tripeptide chelator (N(3)S) and a PEG(2) linker were synthesized and radiolabeled with Tc-99m. The number of -COOH groups on the chelator was altered to increase the excretion of the radiotracer from blood stream via the renal-urinary pathway and to decrease its hepatobiliary uptake. Biodistribution of the radiolabeled conjugates was evaluated in healthy CF-1™ mice at 1h post-injection. The results revealed that the Tc-99m labeled probestin conjugate preferentially (>85% injected dose) excreted via the renal route when an aspartic acid residue was added to the linker (conjugate 4). These results suggest that the pharmacokinetic properties of probestin-based APN-targeted agents could be optimized by adding an appropriate amino acid residue in between the linker and the payload.
Probestin 是一种有效的氨基肽酶 N(APN)抑制剂。合成了 4 种含有三肽螯合剂(N(3)S)和 PEG(2)连接子的 Probestin 缀合物,并将其用 Tc-99m 放射性标记。改变螯合剂上 -COOH 基团的数量,以增加放射性示踪剂通过肾脏-尿液途径从血流中的排泄,并减少其肝胆摄取。在注射后 1 小时,在健康的 CF-1™ 小鼠中评估了放射性标记缀合物的生物分布。结果表明,当在连接子中添加天冬氨酸残基时(缀合物 4),Tc-99m 标记的 Probestin 缀合物优先(>85% 注射剂量)通过肾脏途径排泄。这些结果表明,通过在连接子和有效载荷之间添加适当的氨基酸残基,可以优化基于 Probestin 的 APN 靶向剂的药代动力学特性。